• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低危终末期肝病模型评分<30 的患者中行活体供肝与尸体供肝原发性肝移植的结局比较。

Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.

机构信息

Departments of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.

Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.

出版信息

Liver Transpl. 2021 Jul;27(7):971-983. doi: 10.1002/lt.25993. Epub 2021 Jun 24.

DOI:10.1002/lt.25993
PMID:33492764
Abstract

Although recent studies have reported favorable outcomes in living donor liver transplantation (LDLT), it remains unclear which populations benefit most from LDLT. This study aims to evaluate LDLT outcomes compared with deceased donor LT (DDLT) according to Model for End-Stage Liver Disease (MELD) score categories. Using data from the United Network for Organ Sharing registry, outcomes were compared between 1486 LDLTs; 13,568 donation after brain death (DBD)-DDLTs; and 1171 donation after circulatory death (DCD)-DDLTs between 2009 and 2018. Because LDLT for patients with MELD scores >30 was rare, all patients with scores >30 were excluded to equalize LDLT and DDLT cohorts. Risk factors for 1-year graft loss (GL) were determined separately for LDLT and DDLT. Compared with LDLT, DBD-DDLT had a lower risk of 30-day (adjusted hazard ratio [aHR], 0.60; P < 0.001) and 1-year GL (aHR, 0.57; P < 0.001). The lower risk of GL was more prominent in the mid-MELD score category (score 15-29). Compared with LDLT, DCD-DDLT had a lower risk of 30-day GL but a comparable risk of 1-year GL, regardless of MELD score category. In LDLT, significant ascites was an independent risk for GL in patients with mid-MELD scores (aHR, 1.68; P = 0.02), but not in the lower-MELD score group. The risk of 1-year GL in LDLT patients with ascites who received a left liver was higher than either those who received a right liver or those without ascites who received a left liver. In LDLT, combinations of MELD scores of 15 to 29, moderate/severe ascites, and the use of a left liver are associated with worse outcomes. These findings help calibrate appropriate patient and graft selection in LDLT.

摘要

尽管最近的研究报告了活体供肝移植(LDLT)的良好结果,但仍不清楚哪些人群从 LDLT 中获益最大。本研究旨在根据终末期肝病模型(MELD)评分类别评估 LDLT 与死后供肝移植(DDLT)的结果。使用 2009 年至 2018 年美国器官共享网络登记处的数据,比较了 1486 例 LDLT;13568 例脑死亡后供体(DBD)-DDLT;和 1171 例循环死亡后供体(DCD)-DDLT。由于 MELD 评分>30 的患者接受 LDLT 较为罕见,因此排除了所有评分>30 的患者,以使 LDLT 和 DDLT 队列均衡。分别确定 LDLT 和 DDLT 患者 1 年移植物丢失(GL)的危险因素。与 LDLT 相比,DBD-DDLT 的 30 天(校正后的危险比[aHR],0.60;P<0.001)和 1 年 GL(aHR,0.57;P<0.001)风险较低。中 MELD 评分类别(评分 15-29)的 GL 风险降低更为显著。与 LDLT 相比,无论 MELD 评分类别如何,DCD-DDLT 的 30 天 GL 风险较低,但 1 年 GL 风险相当。在 LDLT 中,中 MELD 评分患者中明显腹水是 GL 的独立危险因素(aHR,1.68;P=0.02),而在低 MELD 评分组中则不是。患有腹水的中 MELD 评分患者接受左肝时 1 年 GL 风险高于接受右肝或无腹水但接受左肝的患者。在 LDLT 中,MELD 评分 15 至 29 分、中度/重度腹水和使用左肝与较差的结果相关。这些发现有助于在 LDLT 中校准适当的患者和移植物选择。

相似文献

1
Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.低危终末期肝病模型评分<30 的患者中行活体供肝与尸体供肝原发性肝移植的结局比较。
Liver Transpl. 2021 Jul;27(7):971-983. doi: 10.1002/lt.25993. Epub 2021 Jun 24.
2
Benefit of living donor liver transplantation in graft survival for extremely high model for end-stage liver disease score ≥35.对于终末期肝病模型评分极高(≥35分)的患者,活体肝移植在移植物存活方面的益处。
J Hepatobiliary Pancreat Sci. 2023 Dec;30(12):1293-1303. doi: 10.1002/jhbp.1376. Epub 2023 Oct 6.
3
Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.比较尸肝和活体肝移植后丙型肝炎复发和纤维化进展:8 年纵向随访。
Transplantation. 2011 Aug 27;92(4):453-60. doi: 10.1097/TP.0b013e3182259282.
4
Survival benefit of living-donor liver transplantation in patients with a model for end-stage liver disease over 30 in a region with severe organ shortage: a retrospective cohort study.在一个器官严重短缺的地区,对于模型预测终末期肝病评分(MELD)超过 30 的患者,活体肝移植的生存获益:一项回顾性队列研究。
Int J Surg. 2023 Nov 1;109(11):3459-3466. doi: 10.1097/JS9.0000000000000634.
5
Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End-Stage Liver Disease Recipients.活体捐赠与循环死亡后肝脏移植在低终末期肝病模型受体中的比较。
Liver Transpl. 2019 Apr;25(4):580-587. doi: 10.1002/lt.25073. Epub 2019 Mar 6.
6
Living Donor Liver Transplantation for Adults With High Model for End-stage Liver Disease Score: The US Experience.成人高终末期肝病模型评分患者的活体肝移植:美国经验。
Transplantation. 2024 Mar 1;108(3):713-723. doi: 10.1097/TP.0000000000004767. Epub 2023 Aug 28.
7
Survival after live donor versus deceased donor liver transplantation: propensity score-matched study.活体供肝与死体供肝肝移植术后生存比较:倾向评分匹配研究。
BJS Open. 2024 May 8;8(3). doi: 10.1093/bjsopen/zrae058.
8
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.在终末期肝病模型分配时代,活体捐赠对肝移植受者生存获益的影响。
Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.
9
Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area.在乙肝流行地区,对终末期肝病模型评分≥35的患者进行活体供肝与尸体供肝肝移植的短期和长期疗效比较
Ann Surg. 2017 Jan;265(1):173-177. doi: 10.1097/SLA.0000000000001671.
10
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.成人对成人活体肝移植队列研究中的复发性原发性硬化性胆管炎:活体供肝与尸体供肝受者的危险因素比较
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.

引用本文的文献

1
Early Graft Failure After Living-Donor Liver Transplant.活体肝移植后早期移植物失功。
Dig Dis Sci. 2024 Apr;69(4):1488-1495. doi: 10.1007/s10620-024-08280-5. Epub 2024 Feb 21.
2
Response to Comment on "Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy: A Promised Land for Small Left Lobe Grafts".对《扩大静脉流出道并脾切除的活体供肝肝移植:小左叶移植物的希望之地》评论的回应
Ann Surg Open. 2023 Mar 17;4(1):e269. doi: 10.1097/AS9.0000000000000269. eCollection 2023 Mar.
3
Recommendations for Evaluation and Selection of Deceased Organ Donor: Position Statement of ISCCM.
已故器官捐献者评估与选择的建议:国际危重症与临床监护医学学会立场声明
Indian J Crit Care Med. 2022 Oct;26(Suppl 2):S43-S50. doi: 10.5005/jp-journals-10071-24190.
4
National experience with living donor liver transplantation for hepatocellular carcinoma.全国范围内活体供肝肝移植治疗肝细胞癌的经验。
Liver Transpl. 2022 Jul;28(7):1144-1157. doi: 10.1002/lt.26439. Epub 2022 Apr 16.